Company news
Hinova Pharmaceuticals, Inc. news in 2024
Hinova Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer
December 30, 2024
Announcement on Share Reduction Plan for Shareholders with Over 5% Shares
December 4, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 4, 2024
Report for Q3 2024
October 25, 2024
Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer
October 15, 2024
Announcement on Expiration of the Shareholding Reduction Plan for Shareholders with Over 5% Shares and Equity Change Reaching 1%
October 14, 2024
Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)
September 13, 2024
Announcement on Attending Semi-annual Collective Performance Briefing 2024 for Pharmaceutical and Biological Products Companies on STAR Market
September 6, 2024
Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP515 Tablets for the Treatment of Non-alcoholic Steatohepatitis (NASH)
August 27, 2024
Semi-annual Report in 2024
August 23, 2024
Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP560 Tablets for the Treatment of Myelofibrosis (Myeloproliferative Neoplasms)
July 24, 2024
Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies
July 7, 2024